MUSC Health Breaks Ground on New Hollings Cancer Center Facility at Florence Medical Center

MUSC Health

Expanding access to advanced oncology services, clinical trials and research for patients across the Pee Dee region

FLORENCE, S.C. (July 2026) – MUSC Health officially broke ground on the future MUSC Hollings Cancer Center at Florence Medical Center, marking a significant milestone in expanding access to comprehensive, state-of-the-art cancer care for patients across the Pee Dee and northeastern South Carolina.

Expected to open in Winter 2027, the new cancer center will be a three-story, 63,000-square-foot facility located on the MUSC Health Florence Medical Center campus. The facility will serve as a regional hub for advanced cancer care, extending the reach of South Carolina’s only National Cancer Institute (NCI)-designated cancer center.

The MUSC Hollings Cancer Center at Florence Medical Center will bring together a comprehensive range of cancer services under one roof, including medical oncology, radiation therapy and infusion therapy. The facility will also provide patients access to clinical trials, research opportunities and specialized therapies, allowing more individuals to receive innovative cancer care close to home.

The groundbreaking represents the next phase of MUSC Health Florence Medical Center’s integration into the MUSC Hollings Cancer Center. Through this network, local physicians and patients gain access to nationally recognized cancer expertise, groundbreaking research, innovative treatments and expanded clinical trial opportunities.

“Today’s groundbreaking marks a transformational moment for healthcare in the Pee Dee,” said Jason Cox, MUSC Health-Pee Dee Division interim CEO and COO. “The MUSC Hollings Cancer Center at Florence Medical Center will bring nationally recognized cancer expertise, advanced treatments and groundbreaking clinical research closer to the patients and families who need them most.”

The center is designed to create a seamless continuum of care for patients at every stage of their cancer journey, beginning with screening and diagnosis and continuing through treatment, survivorship and supportive care. By bringing together multidisciplinary cancer services in a dedicated facility, MUSC Health aims to enhance patient convenience, improve coordination among care teams and expand access to emerging therapies.

The new facility also reflects MUSC Health’s commitment to increasing participation in cancer research and clinical trials across the state. Through the MUSC Hollings Cancer Center, patients in the Pee Dee will have greater opportunities to participate in studies evaluating promising new treatments and therapies that may not otherwise be available in community settings.

“As South Carolina’s only National Cancer Institute-designated cancer center, MUSC Hollings Cancer Center is committed to ensuring that patients throughout the state have access to the most advanced cancer treatments and clinical trials available,” said Raymond N. DuBois, M.D., Ph.D., Hollings Cancer Center director. “This new facility extends that mission by bringing innovative therapies, leading-edge research and multidisciplinary expertise directly to the Pee Dee so more patients can receive exceptional cancer care close to home.”

The MUSC Health Hollings Cancer Center at Florence Medical Center is expected to become a cornerstone of cancer care delivery in the region, furthering MUSC Health’s mission to improve health outcomes and expand access to high-quality, compassionate care for all South Carolinians.

                                                                                      ###

About MUSC


Founded in 1824 in Charleston, MUSC is the state’s only comprehensive academic health system, with a mission to preserve and optimize human life in South Carolina through education, research and patient care. Each year, MUSC educates nearly 3,500 students in six colleges and trains more than 1,060 residents and fellows across its health system. MUSC leads the state in research funding from the National Institutes of Health, including National Institute of General Medical Sciences COBRE awards. For information on our academic programs, visit musc.edu.

As the health care system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest-quality and safest patient care while educating and training generations of outstanding health care providers and leaders to serve the people of South Carolina and beyond. In 2025, for the 11th consecutive year, U.S. News & World Report named MUSC Health University Medical Center in Charleston the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit muschealth.org.

MUSC has a total enterprise annual operating budget of $10.1 billion. The more than 36,200 MUSC members include world-class faculty, physicians, specialty providers, scientists, contract employees, affiliates and care team members who deliver groundbreaking education, research and patient care.

About MUSC Hollings Cancer Center

MUSC Hollings Cancer Center is South Carolina’s only National Cancer Institute-designated cancer center with the largest academic-based cancer research program in the state. With more than 150 faculty cancer scientists and 20 academic departments, it has an annual research funding portfolio of more than $50 million and sponsors more than 200 clinical trials across the state. Hollings offers state-of-the-art cancer screenings, diagnostic capabilities, therapies and surgical techniques within its multidisciplinary clinics to provide the full range of cancer care. Dedicated to preventing and reducing the cancer burden statewide, the Hollings Office of Community Outreach and Engagement works with community organizations to bring cancer education and prevention information to affected populations. For more information visit, hollingscancercenter.musc.edu.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Paige Durham

SCbio is pleased to welcome Paige Durham to the team as communications coordinator to creatively and effectively communicate the value of the life science association’s programs and initiatives.

Durham will be responsible for developing and distributing high-quality content across multiple communications channels to build, advance and grow South Carolina’s life sciences industry, a key business sector for economic prosperity for the Palmetto State.

“SCbio is excited to welcome Paige to our team as our new communications coordinator. Paige brings fresh ideas and a strong background in communications that will be invaluable as we continue to strengthen our engagement with our audience,” said SCbio President and CEO James Chappell. “We are confident that her skills and experience will be crucial in advancing our communication strategies and supporting our mission.”

Before joining SCbio, Durham was the Membership and Communications Manager at the South Carolina Pharmacy Association (SCPhA), where she used her photography, design and writing skills to create content tailored to pharmacy professionals. Durham’s effective communication skills guaranteed the delivery of brand-specific material that captured the eye of her audience.

During her time at SCPhA, Durham created and edited the Palmetto Pharmacist Journal, using her creative vision to showcase members, educational institutions and industry news. Her communications efforts successfully gained new followers for the organization over the course of a year, increasing brand visibility and promoting the pharmacy profession.

Durham holds a Bachelor of Science in hospitality and tourism management and a Bachelor of Science in business administration from the College of Charleston.

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.